Delivery Order SPE2DB20D1004-SPE2DB25FNGQG
- Not listed
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a $34,076.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injectors. This non-competitive, non-set-aside delivery order is scheduled for ultimate completion on July 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,996.67 for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on August 26, 2025, with an ultimate completion date of August 27, 2025. This is a firm fixed-price, non-set-aside contract to be performed at the company's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal pharmaceutical supply relationship,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injections valued at $11,887.80. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors with a ceiling value of $4,379.74 and ultimate completion date of September 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open competition. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency (DLA) awarded a $1,172.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors on August 18, 2025, with completion expected by August 19, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's existing pharmaceutical supply framework. The pharmaceutical distributor will fulfill this order from its corporate office...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $98,947 by the Defense Logistics Agency for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injections, with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order execution under...
- The Defense Logistics Agency awarded a $14,089.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB25FNGQGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,465.19 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply transaction supporting the Defense Health Agency and military healthcare systems' medical procurement needs. This delivery order is executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen fulfills extensive orders across multiple therapeutic domains including specialty medications, brand-name and generic drugs, vaccines, and medical devices. The company's demonstrated capability to compete successfully across DLA's pharmaceutical supply chain and serve defense healthcare systems positions it as a primary supplier for military and veteran medical requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 4/24/25 |